Regis College Senior Honors Program
Thesis - Open Access
Number of Pages
Tuberculosis (TB) is a bacterial disease treated with antibiotics. But because of the prevalence, nature, and lengthy treatment of the disease, TB is in need of new antibiotics. But, big pharma companies, who have historically been responsible for developing many of the world’s critical antibiotic agents, have significantly decreased investment in antibiotic research and development (R&D). Many sectors are devoted to addressing this issue including non-profit, commercial, government, and academia. Specifically in academia and regards to TB, Regis University has pursued research in the identification of inhibitors of Mycobacterium tuberculosis class IIa fructose-1,6-bisphosphate aldolase (MtFBA), an essential enzyme in Mycobacterium tuberculosis. If successful, these inhibitors could serve as potential scaffolds for future therapeutic agents to combat TB. The antibiotic funding problem cannot be tackled without significant cooperation and collaboration. The issue should be addressed with increased collaboration between small biotech companies and big pharma, increased publicity for bacterial diseases, reevaluation of clinical trials, and inspiring the next generation of chemists to simply do science.
Date of Award
Colorado (state); Denver (county); Denver (inhabited place)
© Gina Morgan
All content in this Collection is owned by and subject to the exclusive control of Regis University and the authors of the materials. It is available only for research purposes and may not be used in violation of copyright laws or for unlawful purposes. The materials may not be downloaded in whole or in part without permission of the copyright holder or as otherwise authorized in the “fair use” standards of the U.S. copyright laws and regulations.
Morgan, Gina, "The Decrease in Antibiotic Funding" (2015). Regis University Student Publications (comprehensive collection). 647.